Neurocognitive and psychosocial outcomes in survivors of childhood leukemia with Down syndrome
Open Access
- 19 January 2024
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 13 (3)
Abstract
Objective: The primary aim of this study was to assess the feasibility of a developmentally tailored neurocognitive assessment in survivors of childhood acute leukemia with Down syndrome (DS‐leukemia). A secondary aim was to compare outcomes in the DS‐leukemia group to a historical comparison group of individuals with DS and no history of childhood cancer.Methods: Survivors of DS‐leukemia (n = 43; 56% male, mean [SD] age at diagnosis = 4.3 [4.5] years; age at evaluation = 15 [7.9] years) completed a neurocognitive assessment battery that included direct measures of attention, executive function, and processing speed, and proxy ratings of attention problems and executive dysfunction. Direct assessment outcomes were compared to a historical comparison cohort of individuals with DS and no history of childhood cancer (DS‐control; n = 117; 56% male, mean [SD] age at evaluation = 12.7 [3.4] years).Results: Rates of valid task completion ranged from 54% to 95%, suggesting feasibility for most direct assessment measures. Compared to the DS‐control group, the DS‐leukemia group had significantly lower completion rates on measures of executive function (p = 0.008) and processing speed (p = 0.018) compared to the DS‐control group. There were no other significant group differences in completion rates. Compared to the DS‐control group, the DS‐leukemia group had significantly more accurate performance on two measures of executive function (p = 0.032; p = 0.005). Compared to the DS‐control group, the DS‐leukemia group had significantly more problems with executive function as identified on proxy ratings (6.5% vs. 32.6%, p = <0.001).Conclusion: Children with Down syndrome (DS) are at increased risk for developing acute leukemia compared to the general population but are systematically excluded from neurocognitive outcome studies among leukemia survivors. This study demonstrated the feasibility of evaluating neurocognitive late effects in leukemia survivors with DS using novel measures appropriate for populations with intellectual developmental disorder.Keywords
Funding Information
- American Lebanese Syrian Associated Charities
- National Institutes of Health (P30 CA21765, P30 GM92666, R01 HD093754, R21 HD082307, T32 CA225590)
This publication has 71 references indexed in Scilit:
- Neuropsychological outcomes of a randomized trial of prednisone versus dexamethasone in acute lymphoblastic leukemia: Findings from Dana-Farber Cancer Institute All Consortium Protocol 00-01Pediatric Blood & Cancer, 2013
- Effect of congenital heart defects on language development in toddlers with Down syndromeJournal of Intellectual Disability Research, 2012
- The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XIJournal of Hematology & Oncology, 2011
- Neurodevelopmental outcomes in children with Down syndrome and congenital heart defectsAmerican Journal of Medical Genetics Part A, 2011
- Updated national birth prevalence estimates for selected birth defects in the United States, 2004–2006Birth Defects Research Part A: Clinical and Molecular Teratology, 2010
- Late-Occurring Neurologic Sequelae in Adult Survivors of Childhood Acute Lymphoblastic Leukemia: A Report From the Childhood Cancer Survivor StudyJournal of Clinical Oncology, 2010
- Comparison of Neurocognitive Functioning in Children Previously Randomly Assigned to Intrathecal Methotrexate Compared With Triple Intrathecal Therapy for the Treatment of Childhood Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2009
- Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndromeBlood, 2009
- Cognitive outcome in children and adolescents treated for acute lymphoblastic leukaemia with chemotherapy onlyActa Paediatrica, 2008
- A multicenter, randomized clinical trial of a cognitive remediation program for childhood survivors of a pediatric malignancy.Journal of Consulting and Clinical Psychology, 2008